Company: XAIR
Filing Date: 2025-06-20
Form Type: 10-K
Source: 0001641172-25-015750
Chunk: 1212

Company: Beyond Air, Inc.
Filing Date: 2025-06-20
Form: 10-K
Item: Item 2
Chunk 1212
---
    ●
    the scope, prioritization and number of our clinical trials and other research and development programs;
  
    ●
    the costs and timing of obtaining certification or regulatory approval for our product candidates;
  
    ●
    the costs of filing, prosecuting, enforcing and defending patent claims and other intellectual property rights;
  
    ●
    the costs of, and timing for, strengthening our manufacturing agreements for production of sufficient clinical quantities of our product candidates;
  
    ●
    the potential costs of contracting with third parties to provide marketing and distribution services for us or for building such capacities internally;
  
    ●
    the costs of acquiring or undertaking the development and commercialization efforts for additional, future therapeutic applications of our product candidates;
  
    ●
    the magnitude of our general and administrative expenses; and
  
    ●
    any cost that we may incur under current and future in-and-out-licensing arrangements relating to our product candidates.

Comparison between Fiscal Years Ended March 31,
2025 and March 31, 2024

Cash Flows

Below is a summary of the statements
of cash flows for the years ended March 31, 2025 and March 31, 2024.

    (in thousands) 
    For The Year Ended March 31, 2025  
    For The Year Ended March 31, 2024 

    Net cash provided by (used in): 

    Operating activities 
    $(38,218) 
    $(56,014)
  
    Investing activities 
    $14,905  
    $(12,235)
  
    Financing activities 
    $16,646  
    $43,167 
  
    Effect of exchange rate changes on cash and cash equivalents 
    $(45) 
    $(77)
  
    Net decrease in cash, cash equivalents and restricted cash 
    $(6,712) 
    $(25,160)

Operating Activities

For the year ended March 31, 2025,
net cash used by operating activities was $38.2 million, which was primarily due to our net loss of $48.5 million which includes $9.1
million of stock-based compensation, $3.0 million of depreciation and amortization, a non-cash loss of $2.4 million on the extinguishment
of debt, an impairment of fixed assets charge $0.5 million, a $0.4 million increase in accounts receivable, a $0.4 million increase in
inventory